• Pre Clinical And Clinical Research

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

• Novel self-labelling mammalian display method for identifying antibodies against membrane proteins in their native configuration • Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development

Late Model Lab and Solid Dose Equipment Available in Massachusetts, USA

Leading asset management company, EquipNet, is working with a leading clinical-stage biopharmaceutical company to sell through surplus laboratory/analytical and solid dose equipment.

NanoSyrinx strengthens board with appointment of Dr Jane Dancer as Non-Executive Director

NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director. Dr Dancer has over 30 years’ experience in business development across biotech, pharma and agrochemicals and her experience will help to drive NanoSyrinx’s ongoing fundraising activities and ambitious growth plans.

Fire Monkey v8 HMW DNA extraction delivers 30Gb+ yield from sequencing on the ONT MinION

Fire Monkey v8 HMW DNA extraction delivers 30Gb+ yield from sequencing on the ONT MinION Increased yield can drive disposable costs for MinION to $35/Gb and for PacBio to <$10/Gb

Neuroscience-focused CRO Transpharmation opening new facility at Discovery Park

Sandwich, Kent, November 4 2020 - Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, is pleased to welcome contract research organisation Transpharmation Ltd as a new tenant.

Arcinova announces major investment in Alnwick site with the installation of the R1000 capsule fill machine from 3P Innovation

Arcinova, a multi-service Contract Development and Manufacturing Organisation (CDMO) based in Alnwick, Northumberland, has recently taken delivery and commissioned the award winning R1000 Robotic Capsule Filler from life-sciences automation company 3P innovation, as part of the ‘Fill-Inova’ project.

Iksuda Therapeutics enters license agreement with University of Goettingen to develop a new generation of antibody drug conjugates

• Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with enhanced therapeutic index • Development to focus on targets associated with haematological and solid tumours

Synthetic Biology start up NanoSyrinx secures capital to develop its fully customisable platform for intra-cellular engineering

NanoSyrinx is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism. The company will focus on direct cytosolic delivery of genome editing enzymes and therapeutic proteins in vivo, with key applications in the cell and gene therapy space.

CTI Clinical Trial and Consulting Services Announce Dosing of First Subject in Janssen’s ENSEMBLE Phase 3 COVID-19 Vaccine Trial

CTI research site is the lead enroller of the study, with dozens of patients randomized in the first week, and more scheduled for dosing in the next several.

Enesi Pharma Appoints Vaccine Development Expert Dr Keith Howard as CSO to Lead ImplaVax® Development

Enesi Pharma is delighted to announce the appointment of Dr Keith Howard as Chief Scientific Officer. Dr Howard is a seasoned vaccine development expert who will lead Enesi’s R&D efforts to develop novel solid-dose vaccines for needle-free delivery for both in-house and partnered programmes, progressing them into clinical development.